Jiayi Xu1,2, Kristin A Guertin1,3, Nathan C Gaddis4, Anne H Agler1,5, Robert S Parker1, Jared M Feldman1, Alan R Kristal6,7, Kathryn B Arnold8, Phyllis J Goodman8, Catherine M Tangen6, Dana B Hancock4, Patricia A Cassano1,9. 1. Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA. 2. Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA. 4. GenOmics, Bioinformatics, and Translational Research Center, Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA. 5. Abbott, Columbus, OH, USA. 6. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 7. Department of Epidemiology, University of Washington, Seattle, WA, USA. 8. SWOG Statistics and Data Management Center, Seattle, WA, USA. 9. Division of Epidemiology, Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
Abstract
BACKGROUND: Vitamin E (vitE) is hypothesized to attenuate age-related decline in pulmonary function. OBJECTIVES: We investigated the association between change in plasma vitE (∆vitE) and pulmonary function decline [forced expiratory volume in the first second (FEV1)] and examined genetic and nongenetic factors associated with ∆vitE. METHODS: We studied 1144 men randomly assigned to vitE in SELECT (Selenium and Vitamin E Cancer Prevention Trial). ∆vitE was the difference between baseline and year 3 vitE concentrations measured with GC-MS. FEV1 was measured longitudinally by spirometry. We genotyped 555 men (vitE-only arm) using the Illumina Expanded Multi-Ethnic Genotyping Array (MEGAex). We used mixed-effects linear regression modeling to examine the ∆vitE-FEV1 association. RESULTS: Higher ∆vitE was associated with lower baseline α-tocopherol (α-TOH), higher baseline γ-tocopherol, higher baseline free cholesterol, European ancestry (as opposed to African) (all P < 0.05), and the minor allele of a missense variant in cytochrome P450 family 4 subfamily F member 2 (CYP4F2) (rs2108622-T; 2.4 µmol/L higher ∆vitE, SE: 0.8 µmol/L; P = 0.0032). Higher ∆vitE was associated with attenuated FEV1 decline, with stronger effects in adherent participants (≥80% of supplements consumed): a statistically significant ∆vitE × time interaction (P = 0.014) indicated that a 1-unit increase in ∆vitE was associated with a 2.2-mL/y attenuation in FEV1 decline (SE: 0.9 mL/y). The effect size for 1 SD higher ∆vitE (+4 µmol/mmol free-cholesterol-adjusted α-TOH) was roughly one-quarter of the effect of 1 y of aging, but in the opposite direction. The ∆vitE-FEV1 association was similar in never smokers (2.4-mL/y attenuated FEV1 decline, SE: 1.0 mL/y; P = 0.017, n = 364), and current smokers (2.8-mL/y, SE: 1.6 mL/y; P = 0.079, n = 214), but there was little to no effect in former smokers (-0.64-mL/y, SE: 0.9 mL/y; P = 0.45, n = 564). CONCLUSIONS: Greater response to vitE supplementation was associated with attenuated FEV1 decline. The response to supplementation differed by rs2108622 such that individuals with the C allele, compared with the T allele, may need a higher dietary intake to reach the same plasma vitE concentration.
BACKGROUND: Vitamin E (vitE) is hypothesized to attenuate age-related decline in pulmonary function. OBJECTIVES: We investigated the association between change in plasma vitE (∆vitE) and pulmonary function decline [forced expiratory volume in the first second (FEV1)] and examined genetic and nongenetic factors associated with ∆vitE. METHODS: We studied 1144 men randomly assigned to vitE in SELECT (Selenium and Vitamin E Cancer Prevention Trial). ∆vitE was the difference between baseline and year 3 vitE concentrations measured with GC-MS. FEV1 was measured longitudinally by spirometry. We genotyped 555 men (vitE-only arm) using the Illumina Expanded Multi-Ethnic Genotyping Array (MEGAex). We used mixed-effects linear regression modeling to examine the ∆vitE-FEV1 association. RESULTS: Higher ∆vitE was associated with lower baseline α-tocopherol (α-TOH), higher baseline γ-tocopherol, higher baseline free cholesterol, European ancestry (as opposed to African) (all P < 0.05), and the minor allele of a missense variant in cytochrome P450 family 4 subfamily F member 2 (CYP4F2) (rs2108622-T; 2.4 µmol/L higher ∆vitE, SE: 0.8 µmol/L; P = 0.0032). Higher ∆vitE was associated with attenuated FEV1 decline, with stronger effects in adherent participants (≥80% of supplements consumed): a statistically significant ∆vitE × time interaction (P = 0.014) indicated that a 1-unit increase in ∆vitE was associated with a 2.2-mL/y attenuation in FEV1 decline (SE: 0.9 mL/y). The effect size for 1 SD higher ∆vitE (+4 µmol/mmol free-cholesterol-adjusted α-TOH) was roughly one-quarter of the effect of 1 y of aging, but in the opposite direction. The ∆vitE-FEV1 association was similar in never smokers (2.4-mL/y attenuated FEV1 decline, SE: 1.0 mL/y; P = 0.017, n = 364), and current smokers (2.8-mL/y, SE: 1.6 mL/y; P = 0.079, n = 214), but there was little to no effect in former smokers (-0.64-mL/y, SE: 0.9 mL/y; P = 0.45, n = 564). CONCLUSIONS: Greater response to vitE supplementation was associated with attenuated FEV1 decline. The response to supplementation differed by rs2108622 such that individuals with the C allele, compared with the T allele, may need a higher dietary intake to reach the same plasma vitE concentration.
Keywords:
zzm321990 CYP4F2zzm321990 ; clinical trial; continental population groups; genome-wide association study; human; male; pulmonary function tests; smoking; vitamin E
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: R Graham Barr; Kimberly J Stemple; Sonia Mesia-Vela; Robert C Basner; Susan J Derk; Paul K Henneberger; Donald K Milton; Brenda Taveras Journal: Respir Care Date: 2008-04 Impact factor: 2.258
Authors: Jacqueline M Major; Kai Yu; Charles C Chung; Stephanie J Weinstein; Meredith Yeager; William Wheeler; Kirk Snyder; Margaret E Wright; Jarmo Virtamo; Stephen Chanock; Demetrius Albanes Journal: J Nutr Date: 2012-03-21 Impact factor: 4.798
Authors: Luigi Ferrucci; John R B Perry; Amy Matteini; Markus Perola; Toshiko Tanaka; Kaisa Silander; Neil Rice; David Melzer; Anna Murray; Christie Cluett; Linda P Fried; Demetrius Albanes; Anna-Maria Corsi; Antonio Cherubini; Jack Guralnik; Stefania Bandinelli; Andrew Singleton; Jarmo Virtamo; Jeremy Walston; Richard D Semba; Timothy M Frayling Journal: Am J Hum Genet Date: 2009-01-29 Impact factor: 11.025
Authors: Jacqueline M Major; Kai Yu; William Wheeler; Hong Zhang; Marilyn C Cornelis; Margaret E Wright; Meredith Yeager; Kirk Snyder; Stephanie J Weinstein; Alison Mondul; Heather Eliassen; Mark Purdue; Aditi Hazra; Catherine A McCarty; Sara Hendrickson; Jarmo Virtamo; David Hunter; Stephen Chanock; Peter Kraft; Demetrius Albanes Journal: Hum Mol Genet Date: 2011-07-05 Impact factor: 6.150
Authors: Patricia A Cassano; Kristin A Guertin; Alan R Kristal; Kathryn E Ritchie; Monica L Bertoia; Kathryn B Arnold; John J Crowley; JoAnn Hartline; Phyllis J Goodman; Catherine M Tangen; Lori M Minasian; Scott M Lippman; Eric Klein Journal: Respir Res Date: 2015-03-11